In vitro antimicrobial effects of commercially available mouth-wetting agents

Special Care in Dentistry

Volumn 31, Issue 4, 2011, Pages 123-128

  Güneri, Pelin ^a   Alpöz, Esin ^a   Epstein, Joel B ^b   Çankaya, Hülya ^a   Ates, Mustafa ^a  

^a EGE UNIVERSITY   (Turkey)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

antimicrobial effects; dry mouth; oral gel; oral rinse; saliva substitutes

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; BIOTENE; BIOXTRA; GLUCOSE OXIDASE; LACTOPEROXIDASE; LYSOZYME; MOUTHWASH; ORAL BALANCE; POLYMER; PROTEIN; SALIVA SUBSTITUTE;

ARTICLE; BACTERIAL COUNT; BACTERIAL LOAD; CANDIDA ALBICANS; DRUG COMBINATION; DRUG EFFECT; DRUG MIXTURE; GEL; HUMAN; LACTOBACILLUS ACIDOPHILUS; MATERIALS TESTING; PH; STREPTOCOCCUS MUTANS;

ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; BACTERIAL LOAD; CANDIDA ALBICANS; COLONY COUNT, MICROBIAL; COMPLEX MIXTURES; DRUG COMBINATIONS; GELS; GLUCOSE OXIDASE; HUMANS; HYDROGEN-ION CONCENTRATION; LACTOBACILLUS ACIDOPHILUS; LACTOPEROXIDASE; MATERIALS TESTING; MOUTHWASHES; MURAMIDASE; POLYMERS; PROTEINS; SALIVA, ARTIFICIAL; STREPTOCOCCUS MUTANS;

EID: 79960125451     PISSN: 02751879     EISSN: 17544505     Source Type: Journal    
DOI: 10.1111/j.1754-4505.2011.00194.x     Document Type: Article

References (50)

1. Gibson G,. Identifying and treating xerostomia in restorative patients. J Esthet Dent 1998; 10: 253-64. (Pubitemid 128763262)
2. Kirstilö V, Lenander-Lumikari M, Söderling E, Tenovuo J,. Effects of oral hygiene products containing lactoperoxidase, lysozyme, and lactoferrin on the composition of whole saliva and on subjective oral symptoms in patients with xerostomia. Acta Odontol Scand 1996; 54: 391-7. (Pubitemid 26420953)
3. Shahdad SA, Taylor C, Barclay SC, Steen IN, Preshaw PM,. A double-blind, crossover study of Biotãne Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia. Eur J Cancer Care 2005; 14: 319-26. (Pubitemid 41787431)
4. Tenovuo J,. Clinical applications of antimicrobial host proteins lactoperoxidase, lysozyme and lactoferrin in xerostomia: efficacy and safety. Oral Dis 2002; 8: 23-9. (Pubitemid 34225549)
5. Nieuw Amerongen AV, Veerman EC,. Current therapies for xerostomia and salivary glad hypofunction associated with cancer therapies. Support Care Cancer 2003; 11: 226-31. (Pubitemid 36723568)
6. Hatti S, Ravindra S, Satpathy A, Kulkarni RD, Parande MV,. Biofilm inhibition and antimicrobial activity of a dentifrice containing salivary substitutes. Int J Dent Hyg 2007; 5: 218-24.
7. Shugars DC, Wahl SM,. The role of the oral environment in HIV-1 transmission. J Am Dent Assoc 1998; 129: 851-8. (Pubitemid 128459421)
8. Berkhout B, Floris R, Recio I, Visser S,. The antiviral activity of the milk protein lactoferrin against the human immunodeficiency virus type 1. Biometals 2004; 17: 291-4. (Pubitemid 38987152)
9. Van Der Strate BW, Beljaars L, Molema G, Harmsen MC, Meijer DK,. Antiviral activities of lactoferrin. Antiviral Res 2001; 52: 225-39. (Pubitemid 33000113)
10. Orsi N,. The antimicrobial activity of lactoferrin: current status and perspectives. Biometals 2004; 17: 189-96. (Pubitemid 38987136)
11. Seganti L, Di Biase AM, Marchetti M, Pietrantoni A, Tinari A, Superti F,. Antiviral activity of lactoferrin towards naked viruses. Biometals 2004; 17: 295-9. (Pubitemid 38987153)
12. Teraguchi S, Wakabayashi H, Kuwata H, Yamauchi K, Tamura Y,. Protection against infections by oral lactoferrin: evaluation in animal models. Biometals 2004; 17: 231-34. (Pubitemid 38987142)
13. Yamaguchi H, Abe S, Takakura N,. Potential usefulness of bovine lactoferrrin for adjunctive immunotherapy for mucosal Candida infections. Biometals 2004; 17: 245-8. (Pubitemid 38987144)
14. Bikker FJ, Ligtenberg AJ, Van Der Wal JE, et al. Immunohistochemical detection of salivary agglutinin/gp-340 in human parotid, submandibular, and labial salivary glands. J Dent Res 2002; 81: 134-9. (Pubitemid 41709796)
15. Bergdahl M,. Salivary flow and oral complaints in adult dental patients. Community Dent Oral Epidemiol 2000; 28: 59-66.
16. Soto-Rojas AE, Kraus A,. The oral side of Sjögren syndrome. Diagnosis and treatment. A review. Arch Med Res 2002; 33: 95-106. (Pubitemid 34223423)
17. Cassolato SF, Turnbull RS,. Xerostomia: clinical aspects and treatment. Gerodontology 2003; 20: 64-77.
18. Khurshudian AV,. A pilot study to test the efficacy of oral administration of interferonalpha lozenges to patients with Sjögren's syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2003; 95: 38-44. (Pubitemid 36886720)
19. Alves MB, Motta AC, Messina WC, Migliari DA,. Saliva substitute in xerostomic patients with primary Sjögren's syndrome: a single-blind trial. Quintessence Int 2004; 35: 392-6. (Pubitemid 38515511)
20. Kelly HM, Deasy PB, Busquet M, Torrance AA,. Bioadhesive, rheological, lubricant and other aspects of an oral gel formulation intended for the treatment of xerostomia. Int J Pharm 2004; 278: 391-406. (Pubitemid 38759511)
21. Porter SR, Scully C, Hegarty AM,. An update of the etiology and management of xerostomia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2004; 97: 28-46. (Pubitemid 38067257)
22. Dirix P, Nuyts S, Van Den Bogaert W,. Radiation-induced xerostomia in patients with head and neck cancer: a literature review. Cancer 2006; 107: 2525-34. (Pubitemid 44845604)
23. Jensen SB, Pedersen AM, Reibel J, Nauntofte B,. Xerostomia and hypofunction of the salivary glands in cancer therapy. Support Care Cancer 2003; 11: 207-25. (Pubitemid 36723567)
24. Sugiura Y, Soga Y, Tanimoto I, et al. Antimicrobial effects of the saliva substitute, Oralbalance, against microorganisms from oral mucosa in hematopoietic cell transplantation period. Support Care Cancer 2008; 16: 421-4.
25. Epstein JB, Emerton S, Le ND, Stevenson-Moore P,. A double-blind crossover trial of Oral Balance gel and Biotene toothpaste versus placebo in patients with xerostomia following radiation therapy. Oral Oncol 1999; 35: 132-7. (Pubitemid 29113054)
26. Gil-Montaya JA, Guardia-Lõpez I, González-Moles MA,. Evaluation of the clinical efficacy of a mouthwash and oral gel containing the antimicrobial proteins lactoperoxidase, lysozyme and lactoferrin in elderly patients with dry mouth-a pilot study. Gerodontology 2008; 25: 3-9.
27. Meyer-Lueckel H, Schulte-Mönting J, Kielbassa AM,. The effect of commercially available saliva substitutes on predemineralized bovine dentin in vitro. Oral Dis 2002; 8: 192-8. (Pubitemid 34815224)
28. Epstein JB, Chin EA, Jacobson JJ, Rishiraj B, Le N,. The relationships among fluoride, cariogenic oral flora, and salivary flow rate during radiation therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998; 86: 286-92. (Pubitemid 128644723)
29. Vernillo AT,. Dental considerations for the treatment of patients with diabetes mellitus. J Am Dent Assoc 2003; 134 (Spec No): 24S-33S.
30. Migliorati CA, Madrid C,. The interface between oral and systemic health: the need for more collaboration. Clin Microbiol Infect 2007; 13 (Suppl 4): 11-6. (Pubitemid 47308186)
31. van Steenberghe D, Van Den Eynde E, Jacobs R, Quirynen M,. Effect of a lactoperoxidase containing toothpaste in radiation-induced xerostomia. Int Dent J 1994; 44: 133-8.
32. Jyoti S, Shashikiran ND, Reddy V V,. Effect of lactoperoxidase system containing toothpaste on cariogenic bacteria in children with early childhood caries. J Clin Pediatr Dent 2009; 33: 299-303.
33. Lenander-Lumikari M, Tenovuo J, Mikola H,. Effects of lactoperoxidase system-containing toothpaste on levels of hypothiocyanite and bacteria in saliva. Caries Res 1993; 27: 285-91.
34. Mulligan R, Navazesh M, Slots J,. Antimicrobial activity of an alcohol-free mouthwash with enzymes. J Dent Res 1992; 71 (Suppl 1): 156.
35. McMillan AS, Tsang CS, Wong MC, Kam AY,. Efficacy of a novel lubricating system in the management of radiotherapy-related xerostomia. Oral Oncol 2006; 42: 842-8. (Pubitemid 44307767)
36. Assev S, Vegarud G, Rölla G,. Growth inhibition of Streptococcus mutans strain OMZ 176 by xylitol. Acta Pathol Microbiol Scand B 1980; 88: 61-3. (Pubitemid 10184093)
37. Sahni PS, Gillespie MJ, Botto RW, Otsuka AS,. In vitro testing of xylitol as an anticario-genic agent. Gen Dent 2002; 50: 340-3.
38. Söderling EM, Ekman TC, Taipale TJ,. Growth inhibition of Streptococcus mutans with low xylitol concentrations. Curr Microbiol 2008; 56: 382-5.
39. Mimica-Dukić N, Bozin B, Soković M, Mihajlović B, Matavulj M,. Antimicrobial and antioxidant activities of three Mentha species essential oils. Planta Med 2003; 69: 413-9. (Pubitemid 36774180)
40. Food and Agriculture Organization of the United Nations and World Health Organization. Food Additive Group Details. 32nd Session of the Codex Alimentarius Commission. Accessed November 6, 2009.
41. Bankar SB, Bule M V, Singhal RS, Ananthanarayan L,. Glucose oxidase-an overview. Biotechnol Adv 2009; 27: 489-501.
42. Appendini P, Hotchkiss JH,. Review of antimicrobial food packaging. Innov Food Sci Emerg Tech 2002; 3: 113-26. (Pubitemid 34650080)
43. Afseth J, Rãlla G,. Clinical experiments with a toothpaste containing amyloglucosidase and glucose oxidase. Caries Res 1983; 17: 472-5.
44. Loimaranta V, Laine M, Söderling E, et al. Effects of bovine immune and non-immune whey preparations on the composition and pH response of human dental plaque. Eur J Oral Sci 1999; 107: 244-50.
45. Stelwagen K, Carpenter E, Haigh B, Hodgkinson A, Wheeler TT,. Immune components of bovine colostrum and milk. J Anim Sci 2009; 87: 3-9. Epub 2008.
46. Pakkanen R, Aalto J,. Growth factors and antimicrobial factors of bovine colostrum. Int Dairy J 1997; 7: 285-97. (Pubitemid 28042752)
47. Kanwar JR, Kanwar RK, Sun X, et al. Molecular and biotechnological advances in milk proteins in relation to human health. Curr Protein Pept Sci 2009; 10: 308-38.
48. Kielbassa AM, Shohadai S P, Schulte-Mönting J,. Effect of saliva substitutes on mineral content of demineralized and sound dental enamel. Support Care Cancer 2001; 9: 40-7. (Pubitemid 32125588)
49. Estrela C, Pécora JD, Souza-Neto MD, Estrela CR, Bammann LL,. Effect of vehicle on antimicrobial properties of calcium hydroxide pastes. Braz Dent J 1999; 10: 63-72.
50. Bellm LA, Epstein JB, Rose-Ped AM, Fu R, Martin PJ, Fuchs HJ,. Assessment of various topical oral formulations by bone marrow transplant recipients. Oral Oncol 2001; 37: 42-9.